shutterstock_1635596416_sundry_photography
Sundry Photography / Shutterstock.com
16 February 2021AmericasRory O'Neill

Amgen antibody patents ‘too broad’, says Fed Circuit

The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Big Pharma
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
7 September 2021   Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.

More on this story

Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Big Pharma
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
7 September 2021   Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.

More on this story

Biotechnology
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Big Pharma
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.
Americas
7 September 2021   Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.